Canary Acuity™

Comprehensive Gene Profiling (CGP)

The Canary Acuity™ Comprehensive Gene Profiling (CGP) test is CLIA-certified and CAP-Accredited for solid and liquid tumors. This test examines 1091 genes, including dozens that are not found in other competing tests, offering a thorough analysis for personalized cancer care. This comprehensive approach enables tailored treatment strategies such as targeted therapy or immunotherapy.

Cancer Types
Solid tumors or liquid tumors
Turnaround Time
14 days from the time the sample is received
Sample Types
FFPE tissue or Peripheral Blood

Test Features

Extensive Gene Testing

Examining 1091 cancer-related genes with clinically relevant treatment options, we provide the most complete diagnostic test available.

Compare with other comapnies

Comprehensive comparison of Canary diagnostic solutions with other comapnies offerings

Note: Green Color highlighted text indicated test results where Canary has a differentiated advantage.
Test Results	Canary Acuity™	Canary Pulse™	Top U.S. and Indian Competitors
Number of Genes Analyzed via NGS	1091 (+637 Variants)	468 (+37 Variants)	300-500
Therapeutic SNVs and InDels	✓	✓	✓
Amplifications and Deletions	✓	✓	✓
Fusions Genes	✓	✓	✓
Tumor Mutational Burden (TMB)	✓	✓	✓
Microsatellite Instability (MSI)	✓	✓	✓
Homologous Recombination Deficiency (HRD)	✓	✓	✓
Loss of Heterozygosity (LOH)	✓	✓	✓
Comprehensive Proprietary Database of FDA Approved/Clinical Trial Drugs for Corresponding Biomarkers	✓	✓	✓
Depiction of Cancer-Relevant Pathways	✓	✓	✗
Germline Variants Affecting Drug Metabolism	✓	✓	✗
Complete ACMG Oncology Germline Mutational Analysis	✓	✓	✗
In Development
TCR Clonality	✓	✗	✗
HLA Typing	✓	✓	✗

Compare with Canary Tests

Comprehensive comparison of Canary diagnostic solutions